FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981036300> ?p ?o ?g. }

• W2981036300 endingPage "5544" @default.
• W2981036300 startingPage "5544" @default.
• W2981036300 abstract "Abstract Background Chronic lymphocytic leukemia (CLL) is a common B-cell lymphoproliferative neoplasm. Although not required for the diagnosis of CLL, important prognostic information is obtained with fluorescence in-situ hybridization (FISH) testing for chromosomal aberrations including del(11q), trisomy 12, del(13q), and del(17p). Abnormalities involving TP53, the ATM gene, and cases constituting complex cytogenetics (3 or more abnormalities), among others, have been shown to impact patient survival and response to traditional chemoimmunotherapy (CIT). Cytogenetic microarray analysis (CMA) is a laboratory technique used to detect unbalanced chromosomal abnormalities. CMA allows for comparison of hundreds of discrete loci within a chromosome and has been validated in CLL, with greater sensitivity in detecting genomic alterations compared to FISH. The acquisition of new genomic alterations is termed clonal evolution and has been shown to have a detrimental effect on survival in patients with CLL (Shanafelt TD, et al. J Clin Oncol. 2006). CIT results in a higher proportion of complete responses (CR) and eradication of CLL clones compared to targeted therapies. While targeted therapies may successfully suppress CLL clones, a CR is rare with single-agent treatment (Byrd JC, et al. Blood. 2015). CMA may be a valuable tool in monitoring clonal evolution throughout a patient's disease course and may have a role in evaluation of patients on suppressive therapies due to the relatively high risk of clonal emergence. Methods This was a single-center retrospective study. Patients with pathologically-confirmed CLL were analyzed utilizing data obtained from the electronic medical record. Data was extracted from the CMA reports and clinic documentation. To be included in the study, at least two serial CMA evaluations were required, separated by at least four weeks. In the interval between CMA results, subsequent systemic treatment was recorded, if any. Treatments were categorized as ibrutinib/idelalisib (I), any cytotoxic chemotherapy (C), and no treatment/observation (N). Change in the number of abnormalities detected by CMA was calculated for each interval and evaluated as both continuous and categorical (increase/no change/decrease). Patients with over three abnormalities were deemed to have complex disease. Genomic DNA of bone marrow or peripheral blood was extracted using Qiagen's Gentra Puregene kit. Chromosome microarray assay was performed using ThermoFisher Affymetrix CytoScan HD according to the manufacturer's protocol. Copy number and allele analysis was performed using Affymetrix Chromosome Analysis Suite using the default settings. Results There were 34 patients who met inclusion criteria, each with 2-4 CMA results, for a total of 81 CMA results. Forty-seven treatment intervals were analyzed. The median age was 61 years, and 64% of patients were male. Based on the first CMA result, the median number of detected abnormalities was 2 and mean was 2.6; 13 patients (38%) had complex disease. Complexity was not associated with a clinically significant change in the number of chromosomal abnormalities regardless of what treatment was received, if any (p=0.14). Overall, 18% of patients (6/34) had a decrease in the number of abnormalities detected by CMA, while 21% (7/34) had an increase. Analyzing the data by treatment group, the mean change in number of abnormalities was -0.5, -0.6 and +0.3, in groups I, C and N, respectively (p=0.26) (Figure 1). Among the patients in group I, 23% (3/13) had a decrease in the number of abnormalities, while 23% demonstrated an increase. For those in group C, 25% (2/8) and 25% experienced increase and decrease, respectively. For patients in group N, 14% (3/21) had an increase and 0% had a decrease in CMA abnormalities. Among the two patients who experienced Richter's transformation, the complexity of their chromosomal abnormalities increased over time and preceded clinical emergence of transformation. Discussion CMA can sensitively identify the emergence or clearance of CLL clones and help detect clonal evolution throughout periods of treatment or observation. Though a relatively small number of patients had serial CMA data for evaluation, these data suggest that CMA should be prospectively analyzed in patients with CLL and may be used as a dynamic clinical tool to potentially modify treatments in patients with sub-clinical evidence of treatment failure. Figure 1. Figure 1. Disclosures Barta: Janssen: Membership on an entity's Board of Directors or advisory committees; Merck, Takeda, Celgene, Seattle Genetics, Bayer: Research Funding." @default.
• W2981036300 created "2019-10-25" @default.
• W2981036300 creator A5009574158 @default.
• W2981036300 creator A5011240474 @default.
• W2981036300 creator A5014868247 @default.
• W2981036300 creator A5019666650 @default.
• W2981036300 creator A5022028917 @default.
• W2981036300 creator A5030553105 @default.
• W2981036300 creator A5037519871 @default.
• W2981036300 creator A5071711909 @default.
• W2981036300 creator A5073646064 @default.
• W2981036300 date "2018-11-29" @default.
• W2981036300 modified "2023-10-16" @default.
• W2981036300 title "Detecting Clonal Evolution in CLL Patients Treated with Targeted Therapies Versus Chemotherapy Utilizing Cytogenetic Microarray Analysis" @default.
• W2981036300 doi "https://doi.org/10.1182/blood-2018-99-119619" @default.
• W2981036300 hasPublicationYear "2018" @default.
• W2981036300 type Work @default.
• W2981036300 sameAs 2981036300 @default.
• W2981036300 citedByCount "0" @default.
• W2981036300 crossrefType "journal-article" @default.
• W2981036300 hasAuthorship W2981036300A5009574158 @default.
• W2981036300 hasAuthorship W2981036300A5011240474 @default.
• W2981036300 hasAuthorship W2981036300A5014868247 @default.
• W2981036300 hasAuthorship W2981036300A5019666650 @default.
• W2981036300 hasAuthorship W2981036300A5022028917 @default.
• W2981036300 hasAuthorship W2981036300A5030553105 @default.
• W2981036300 hasAuthorship W2981036300A5037519871 @default.
• W2981036300 hasAuthorship W2981036300A5071711909 @default.
• W2981036300 hasAuthorship W2981036300A5073646064 @default.
• W2981036300 hasConcept C104317684 @default.
• W2981036300 hasConcept C113968399 @default.
• W2981036300 hasConcept C121608353 @default.
• W2981036300 hasConcept C124942203 @default.
• W2981036300 hasConcept C126322002 @default.
• W2981036300 hasConcept C143998085 @default.
• W2981036300 hasConcept C174475383 @default.
• W2981036300 hasConcept C203014093 @default.
• W2981036300 hasConcept C2776229224 @default.
• W2981036300 hasConcept C2776694085 @default.
• W2981036300 hasConcept C2776755627 @default.
• W2981036300 hasConcept C2777542201 @default.
• W2981036300 hasConcept C2777938653 @default.
• W2981036300 hasConcept C2778461978 @default.
• W2981036300 hasConcept C2779263901 @default.
• W2981036300 hasConcept C2780790343 @default.
• W2981036300 hasConcept C30481170 @default.
• W2981036300 hasConcept C54355233 @default.
• W2981036300 hasConcept C71924100 @default.
• W2981036300 hasConcept C86803240 @default.
• W2981036300 hasConceptScore W2981036300C104317684 @default.
• W2981036300 hasConceptScore W2981036300C113968399 @default.
• W2981036300 hasConceptScore W2981036300C121608353 @default.
• W2981036300 hasConceptScore W2981036300C124942203 @default.
• W2981036300 hasConceptScore W2981036300C126322002 @default.
• W2981036300 hasConceptScore W2981036300C143998085 @default.
• W2981036300 hasConceptScore W2981036300C174475383 @default.
• W2981036300 hasConceptScore W2981036300C203014093 @default.
• W2981036300 hasConceptScore W2981036300C2776229224 @default.
• W2981036300 hasConceptScore W2981036300C2776694085 @default.
• W2981036300 hasConceptScore W2981036300C2776755627 @default.
• W2981036300 hasConceptScore W2981036300C2777542201 @default.
• W2981036300 hasConceptScore W2981036300C2777938653 @default.
• W2981036300 hasConceptScore W2981036300C2778461978 @default.
• W2981036300 hasConceptScore W2981036300C2779263901 @default.
• W2981036300 hasConceptScore W2981036300C2780790343 @default.
• W2981036300 hasConceptScore W2981036300C30481170 @default.
• W2981036300 hasConceptScore W2981036300C54355233 @default.
• W2981036300 hasConceptScore W2981036300C71924100 @default.
• W2981036300 hasConceptScore W2981036300C86803240 @default.
• W2981036300 hasIssue "Supplement 1" @default.
• W2981036300 hasLocation W29810363001 @default.
• W2981036300 hasOpenAccess W2981036300 @default.
• W2981036300 hasPrimaryLocation W29810363001 @default.
• W2981036300 hasRelatedWork W1968147293 @default.
• W2981036300 hasRelatedWork W1976636958 @default.
• W2981036300 hasRelatedWork W1980088271 @default.
• W2981036300 hasRelatedWork W1988877261 @default.
• W2981036300 hasRelatedWork W2042688319 @default.
• W2981036300 hasRelatedWork W2072921368 @default.
• W2981036300 hasRelatedWork W2077928458 @default.
• W2981036300 hasRelatedWork W2078673385 @default.
• W2981036300 hasRelatedWork W2563267966 @default.
• W2981036300 hasRelatedWork W2981036300 @default.
• W2981036300 hasVolume "132" @default.
• W2981036300 isParatext "false" @default.
• W2981036300 isRetracted "false" @default.
• W2981036300 magId "2981036300" @default.
• W2981036300 workType "article" @default.